Reported Reactions

Devices › Device types

FDA product code MBX · class 3 · Unknown

Stimulator, thalamic, epilepsy, implanted: medical device reports filed with FDA

416 reports carry this product code, 2018–2026; 5 brands with a page.

416
reports with this product code
0% of all MAUDE reports
87
reports, 12 months to August 2026
79 in the 12 months before
52.9%
classified as malfunction
62.3% across all reports
0.5%
classified as death, as reported
0.9% across all reports

Product code MBX is FDA's classification for "Stimulator, thalamic, epilepsy, implanted" (unknown panel), a class 3 device. 416 medical device reports carry this product code, 0% of the MAUDE database, from June 2018 to August 2026.

87 reports arrived in the 12 months to August 2026, up 10% from 79 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (52.9%), injury (46.6%) and death (0.5%). 5 brand names with a page on this site carry this code; the brands table is ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Brands with this product code

BrandReportsLatest 12 monthsClassified as deathClassified as malfunction
Percept721,2390.3%58.6%
Activa441,1120.6%60.8%
Sensight222501.6%74.4%
Soletra2124.2%48%
Primeadvanced1160%48.1%

Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Manufacturers named

Manufacturer (as written on reports)ReportsShare
Medtronic Neuromodulation7016.8%
Medtronic Europe Sarl92.2%
Medtronic Neurosurgery10.2%

Reports by month, five years

0713Sep 2021: 3Oct 2021: 3Nov 2021: 1Dec 2021: 12022Jan 2022: 4Feb 2022: 3Mar 2022: 4Apr 2022: 7May 2022: 2Jun 2022: 1Jul 2022: 1Aug 2022: 6Sep 2022: 3Oct 2022: 3Nov 2022: 9Dec 2022: 12023Jan 2023: 3Feb 2023: 7Mar 2023: 8Apr 2023: 4May 2023: 6Jun 2023: 3Jul 2023: 2Aug 2023: 10Sep 2023: 5Oct 2023: 4Nov 2023: 8Dec 2023: 22024Jan 2024: 5Feb 2024: 11Mar 2024: 3Apr 2024: 2May 2024: 10Jun 2024: 1Jul 2024: 8Aug 2024: 10Sep 2024: 4Oct 2024: 6Nov 2024: 4Dec 2024: 92025Jan 2025: 10Feb 2025: 6Mar 2025: 11Apr 2025: 6May 2025: 7Jun 2025: 3Jul 2025: 10Aug 2025: 3Sep 2025: 4Oct 2025: 9Nov 2025: 7Dec 2025: 72026Jan 2026: 7Feb 2026: 4Mar 2026: 7Apr 2026: 11May 2026: 5Jun 2026: 6Jul 2026: 7Aug 2026: 13

FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.

Event type and report source

Event type

Death0.5%2
Injury46.6%194
Malfunction52.9%220
Other0%0
Not given0%0

Who filed

Manufacturer report99%412
Voluntary report0.7%3
User facility report0%0
Distributor report0%0
Not given0.2%1

Grey bar: all 26,136,888 MAUDE reports.

Device problems coded

Device problem (FDA code)ReportsShare
High impedance7818.8%
Insufficient device problem information5513.2%
Battery problema problem with the battery419.9%
Failure to deliver energy389.1%
Breakthe device broke307.2%
Communication or transmission problemthe device could not communicate or transmit256%
Malposition of device204.8%
Charging problem194.6%
Low impedance184.3%
Migration or expulsion of device174.1%
Impedance problem153.6%
Display or visual feedback problem133.1%
Inappropriate/inadequate shock/stimulation133.1%
Connection problema connection problem112.6%
Failure to interrogate112.6%
Material integrity problema problem with the device material112.6%
Electromagnetic compatibility problem92.2%
Failure to power up92.2%
Energy output problem81.9%
Therapeutic or diagnostic output failure81.9%

Questions about stimulator, thalamic, epilepsy, implanted reports

What is product code MBX?

FDA's classification code for "Stimulator, thalamic, epilepsy, implanted", class 3, reviewed by the unknown panel. Every device report carries the product code of the device involved.

How many reports carry this code?

416 reports through August 2026, 87 of them in the latest 12 months.

Which brands appear most often?

Percept (72), Activa (44), Sensight (22), Soletra (2) and Primeadvanced (1). Widely used products collect more reports because more people use them.

Can the brands table be used to rank the devices?

No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." Brands differ in how many are in use, how long they have been sold and how reports are collected.

Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.